summari report sale
organ growth adjust ep sale ahead
consensu adjust ep ahead
consensus/our estim addit withdrew
guidanc given uncertainti regard durat
impact view deliv three key messag
call confid diversifi busi model
split consum demand orient
busi hospit demand orient busi see
sign stabil china believ see
recoveri elect procedur year
geographi track achiev meaning increas
diagnost test id
serolog test igg later flow provid project
potenti test contribut later note
chang estim rais price target lower
sale estim organ
lower adjust ep estim lower
sale estim organ
rais adj ep estim
increas price target base
ep estim would note estim
rel conserv catch addit
diagnost estim includ less half potenti
test potenti given know long
test need competit landscap remain
sale beat across key segment organ sale growth
ex-fx deceler though
still exceed estim adjust covid-
adjust sale guidanc organ
growth us sale organ beat
estim ou sale organ also exceed
estim note fx bp headwind
report sale better model
nutrit sale beat consensu
estim reflect pandemic-rel stock stock
impact pediatr nutrit includ us
ou per total organ nutrit growth
acceler exclud stock
total nutrit would grown
continu follow page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort intang ep continu
oper ep includ stj amo alr deal
compani data secur llc estim reuter
continu previou page
diagnost dx sale came ahead consensu forecast organ
growth slow reflect declin lab routin test
volum fell pandem partli off-set strong growth molecular
test expand ou point care poc benefit relat bedsid test
medic devic sale exceed consensu estim report
basi organ growth slow still impact
adjust estim cardiovascular neuromodul busi face
headwind expect heart failur urgent natur sale grew organ
addit diabet sale grew organ slightli reflect strong
libr sale vs estim
epd establish pharmaceut sale beat consensu forecast
organ growth slow slightli note stock
relat benefit epd quarter
ep in-lin adjust ep ahead consensu estim guidanc
includ impact rel model ep beat larg reflect higher
revenu lower sg vs estim slightli lower tax rate vs
estim report revenu exceed consensu estim
guidanc withdrawn frame think suspend full
year guidanc due uncertainti regard durat impact line
med-tech peer compani believ posit give qualit comment
point earn call provid color commentari think
impact break busi two group hospital-bas demand
gener busi consumer-bas demand busi split size
consumer-bas demand busi epd nutrit diabet perform
line exist expect pre-covid quarter ex us ped nutrit go forward
see consumer-demand busi perform kind trend seen histor
except nutrit may adjust bit given stock move hospital-bas busi
surpris acut impact medic devic lab diagnost
discuss compani note last week march
lab cardiovascular medic devic across core market larger categori
cardiovascular period electrophysiolog ep declin stent
structur heart addit neuromodul exit last week
march
libr remain resili mention work finish item libr
 libr franchis post sale slightli estim
repres flat sequenti growth attribut us perform larg shipment time
rebat script grew patient add quarter-end robust us
see franchis slow us believ remain resili rel area
med-tech ou libr print estim repres
ex-fx y/i growth regard libr note work finish item
regard open item fda though updat timelin provid
diagnost benefit increasingli test start late march
launch molecular diagnost test id rapid point-of-car platform
lab platform compani also plan launch lab-bas serolog test
detect antibodi igg commit manufactur id test per day april
deliv cadenc thu far alreadi ship test march intend
ship antibodi test april said alreadi order
antibodi test expect ramp capac test per-month june beyond
compani also plan develop later flow serolog base test
rapid molecular busi diagnost see posit growth quarter
respect signific covid benefit test sale
quarter given test launch late march potenti covid test much
signific beyond revenu standpoint model follow page illustr
potenti benefit abt diagnost test platform note current
model bake fraction potenti benefit test given uncertainti
time long test need potenti competit dynam
see improv trend china anticip recoveri row
back level seen decemb januari note china busi show
improv trend march china sale februari week week basi start
see trend toward pre-covid level addit see sign recoveri market
asia smaller european countri area world said start see
flatten stabil suggest speed viru littl bit control go
forward note see potenti recoveri clearli
challeng quarter year though elect procedur get defer believ lifesav
cardiovascular procedur stent pacer mitral valv repair return said
believ catch elect procedur come back speed came
like given hospit capac model med-tech conserv assum recoveri
begin
messag capit alloc chang recal past year
focus pay debt stj alr acquisit compani signific financi
view howev manag note call expect
philosophy/framework go forward name compani see anyth meet
threshold moment remain focus execut exist portfolio manag
note continu believ diversifi approach strong confid intern
pipelin addit note typic buy back stock except off-set dilut
mention consist histori increas dividend
price target
price target base ep estim risk target includ
slower growth key busi market delay stj alr integr slower margin
expect continu deliv double-digit underli ep growth mid high-singl digit
underli sale growth oper leverag
abbott laboratori diversifi global medic product compani four key busi segment
nutrit diagnost establish pharmaceut epd medic devic compani report
total revenu compani acquir stj januari nearli doubl
